Company Description

Aveta Biomics is a clinical-stage biotechnology company developing a new class of oral immunomodulatory therapies designed to reprogram the tumor microenvironment and improve outcomes across multiple cancers. Its lead program, APG-157, is being evaluated in a global Phase 3 trial for head and neck cancer.